Primidone Dosing
For adults and children over 8 years, start primidone at 100-125 mg at bedtime and gradually titrate over 10 days to a maintenance dose of 750 mg/day (250 mg three times daily), with a maximum of 2000 mg/day if needed. 1
Adult Dosing (≥8 years)
Initial Titration Schedule
The FDA-approved initiation regimen follows a structured 10-day titration 1:
- Days 1-3: 100-125 mg at bedtime
- Days 4-6: 100-125 mg twice daily
- Days 7-9: 100-125 mg three times daily
- Day 10 onward: 250 mg three times daily (maintenance)
Maintenance Dosing
- Standard maintenance: 750-1000 mg/day in divided doses (250 mg 3-4 times daily)
- Maximum dose: 2000 mg/day (500 mg four times daily) if required 1
- Therapeutic serum level: 5-12 mcg/mL 1
Important Clinical Consideration for Essential Tremor
Research demonstrates that low-dose primidone (250 mg/day) is equally or more effective than high doses (750 mg/day) for essential tremor control, with significantly fewer side effects and better tolerability 2. The dropout rate due to adverse effects was significantly higher in the high-dose group (p<0.03) 2. For essential tremor specifically, consider maintaining patients at 250 mg/day rather than escalating to standard epilepsy doses.
Pediatric Dosing (<8 years)
Initial Titration Schedule 1
- Days 1-3: 50 mg at bedtime
- Days 4-6: 50 mg twice daily
- Days 7-9: 100 mg twice daily
- Day 10 onward: 125-250 mg three times daily (maintenance)
Maintenance Dosing
- Weight-based: 10-25 mg/kg/day in divided doses
- Typical range: 125-250 mg three times daily 1
For neonates and young infants with refractory seizures: 25 mg/kg/day in 3 divided doses achieves therapeutic levels by day 3, with seizure control typically occurring within 5 days 3.
Elderly Patients
No specific dose reduction is mandated based on age alone for primidone, unlike many other medications. However, use the standard adult titration schedule with careful monitoring for adverse effects. If renal function is impaired (common with aging), adjust dosing accordingly based on creatinine clearance, though specific guidelines are not well-established in the literature.
Switching from Other Anticonvulsants
When transitioning to primidone monotherapy 1:
- Start primidone at 100-125 mg at bedtime
- Gradually increase primidone to maintenance levels
- Simultaneously taper the other anticonvulsant gradually
- Complete the transition over at least 2 weeks minimum
Critical Pitfall to Avoid
Acute primidone toxicity (severe dizziness, sedation) is common when initiating therapy. Up to one-third of patients may fail to tolerate initial doses 4. This can be prevented by:
Phenobarbital pretreatment strategy: Pretreat with phenobarbital for several days before starting primidone at 500 mg/day, then stop phenobarbital. This exploits cross-tolerance and allows 87% of patients to tolerate primidone introduction with minimal adverse events 5.
Very gradual titration: The standard 10-day titration schedule minimizes but doesn't eliminate early side effects. Starting lower (even 50 mg) may help in sensitive patients, though one study found no significant benefit from ultra-low suspension dosing 4.
Single-dose test: A single 250 mg dose can decrease tremor by 60% within 1-7 hours, allowing assessment of both efficacy and tolerability before committing to chronic therapy 6.
Key Monitoring Parameters
- Serum levels: Therapeutic range 5-12 mcg/mL for primidone 1
- Also measure phenobarbital levels: Primidone is metabolized to phenobarbital (active metabolite), and the conversion rate varies widely between individuals 7
- Phenylethylmalonamide (PEMA): Another active metabolite that contributes to efficacy, particularly in neonates where seizure control correlates with primidone and PEMA levels rather than phenobarbital 3
Special Considerations
Renal impairment: Specific dosing adjustments are not well-defined in guidelines, but monitor closely and consider dose reduction with significant impairment.
Hepatic impairment: No specific guidelines available; use with caution.
Drug interactions: Primidone is a potent enzyme inducer (via phenobarbital metabolite) affecting CYP3A4 substrates.